Clinical trials of single-agent trastuzumab (Herceptin)

Seminars in Oncology

Volumn 27, Issue 5 SUPPL. 9, 2000, Pages 20-26

  Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENE PRODUCT; MEMBRANE PROTEIN; MEMBRANE PROTEIN HER2; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALOPECIA; BREAST CARCINOGENESIS; BREAST CARCINOMA; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TARGETING; GENE OVEREXPRESSION; HEART DISEASE; HUMAN; MUCOSA INFLAMMATION; NEUTROPENIA; ONCOGENE NEU; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; DRUG EVALUATION, PRECLINICAL; HUMAN; RECEPTOR, ERBB-2; SUPPORT, NON-U.S. GOV'T;

EID: 0033770667     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. ErbB receptors and EGF-like ligands: Cell lineage determination through combinatorial signaling
2. Receptor protein-tyrosine kinases and their signal transduction pathways
3. Roles of ErbB3 and ErbB4 in the physiology and pathology of the mammary gland
4. EGF-related peptides and their receptors in mammary gland development
5. EGF-related peptides in the pathophysiology of the mammary gland
6. Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland
7. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH3T3 cell
8. erbB-2 is a potent oncogene when overexpressed in NIH-3T3 cells
9. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
10. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
11. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
12. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
13. Humanization of an anti-p185HER2 antibody for human cancer therapy
14. Development and characterization of a rhuMAb HER2 antibody assay for clinical evaluation of cytotoxic potency
15. Antibody dependent cell-mediated cytotoxicity in breast cancer patients in phase Ill clinical trials of a humanized anti-HER2 antibody
16. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product
17. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
18. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth
19. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells
20. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
21. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER 2 blocks crosstalk with growth factor receptors
22. Effects of the 4D5 antibody on HER2/neu heterodimerization with other class I receptors in human breast cancer cells
23. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
24. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer
25. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
26. Efficacy and safety of Herceptin (trastuzumab humanized anti-HER2 antibody) as a single agent in first line treatment of HER2 overexpressing metastatic breast cancer (HER2+/MBC)
27. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells
28. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial